Christopher Gerry
Vermögen: 25 960 $ am 31.07.2026
Vermögen: 25 960 $ am 31.07.2026
Christopher W.
Gerry is currently Secretary & General Counsel at Faeth Therapeutics, Inc., a position starting in 2026.
Formerly, Mr. Gerry was Vice President & Deputy General Counsel at AVROBIO, Inc. from 2021 to 2022 and an Associate at Cooley LLP from 2013 to 2019.
Education includes undergraduate studies at Dickinson College and graduate studies at Boston University School of Law.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.06.2026 | 953 ( 0% ) | 25 960 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FAETH THERAPEUTICS, INC. | General Counsel | 01.07.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | 01.07.2022 |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01.10.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Dickinson College
Dickinson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Boston University School of Law
Boston University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AVROBIO, Inc.
AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops immunotherapies for cancers and infectious disease | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen